inkagE between GAstrointestinal Symptom and CoronarY stenting study
Not Applicable
Recruiting
- Conditions
- Coronary artery disease
- Registration Number
- JPRN-UMIN000011996
- Lead Sponsor
- Graduate School of Medical Sciences,Kumamoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
allergy to rabeprazole severe liver, or renal dysfunction, heart failure, malignancy, gastroduodenal injury, taking warfarin,
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method to examine cardiovascular events, and gastrointestinal lesions at 1 month between rabeprazole and placebo groups
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways connect gastrointestinal inflammation to coronary stenting outcomes in the LEGACY study?
How does the LEGACY study's interventional approach compare to standard coronary stenting for CAD patients with GI comorbidities?
Which biomarkers (e.g., CRP, IL-6) predict response to coronary stenting in patients with gastrointestinal symptoms?
What adverse events are reported in the LEGACY study for coronary stenting patients with GI symptom profiles?
Are antiplatelet agents or proton pump inhibitors evaluated as combination therapies in the LEGACY study for GI-related CAD risks?